基于抗体的纳米粒子在阿尔茨海默氏症:诊断和治疗的创新
Faheem Patwekar1, Mohsina Patwekar2, Lee Seong Wei3
1Department of Agriculture Science, Faculty of Agro-Based Industry, Universiti Malaysia Kelantan, Jeli, Kelantan 17600, Malaysia; Department of Pharmacognosy, Luqman College of Pharmacy, PB 86, Old Jewargi road, Gulbarga, Karnataka, India.
Pathology, research and practice
|February 28, 2026
概括
抗体纳米粒子提供了新的方法来诊断和治疗阿尔茨海默病 (AD) 通过改善药物输送穿过血脑屏障. 克服制造和安全方面的挑战是临床成功的关键.
科学领域:
- 神经科学和纳米技术
- 生物医学工程 生物医学工程
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β斑块,陶,神经炎症和血脑屏障 (BBB) 功能障碍.
- 目前针对阿尔茨海默氏症的抗体疗法面临着诸如脑透能力差,免疫性和高成本等局限性.
- 基于抗体的纳米粒子平台正在成为AD诊断和治疗的先进解决方案.
研究的目的:
- 审查基于抗体的纳米颗粒用于AD诊断和治疗.
- 专注于纳米粒子设计,抗体结合,BBB运输机制和免疫调节.
- 评估当前的翻译挑战和这些平台的未来方向.
主要方法:
- 对AD的抗体功能化纳米颗粒的临床前研究的审查.
- 分析各种纳米粒子材料 (黄金,磁性,聚合物,基于脂质).
- 检查加强BBB传输和调节神经炎症的策略.
主要成果:
- 抗体纳米颗粒通过受体介导的细胞转移改善了标特异性和BBB传输.
- 纳米粒子系统显示了治疗和分子成像 (MRI,PET) 的潜力.
- 挑战包括纳米粒子不稳定性,免疫清除,毒性和制造可扩展性.
结论:
- 基于抗体的纳米颗粒对精确的AD诊断和向治疗充满希望.
- 临床翻译需要标准化的制造,安全评估和精心设计的试验.
- 未来的工作包括theranostic系统,多目标方法和监管框架.
相关概念视频
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K